HUTCHMED (China) Limited (HCM)

Nasdaq: HCM · Pharmaceutical Preparations · Hong Kong · filing with the SEC since 2015

Full chart Alerts Compare

Grade6.0

◀ Past 7.0● Present 6.7▶ Future 4.0

1 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of HUTCHMED (China) Limited

Nine metrics read from its own filings, by tense

Headline grade

6.0/10

◀ Past7.030% of the headline

● Present6.740% of the headline

▶ Future4.030% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

7.0/1030% of the headline grade · 3 of 3 filed

Surviving crises

as filed

8.2/10

Has it survived what it has been through?

No warning events in its filings since 2017.

weight 33% of this tense · 82nd percentile among 497 sector filers · read for itself

From the record

HUTCHMED (China) Limited's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

5.8/10

What has it actually done, year after year?

+10.9% a year over 10 filed years; profitable in 4 of 10.

weight 45% of this tense · 58th percentile among 323 sector filers · read for its customers

From the record

HUTCHMED (China) Limited's 10 filed years say what it did: revenue went from $216 million in fiscal 2016 to $549 million in fiscal 2025, up 10.9% a year; it rose in 5 of 9 years; the deepest fall was 35% from fiscal 2023 to fiscal 2025; net income was positive in 4 of 10 of those years (its annual reports).

What it rests on

revenue growth over the filed span10.9%bottom 46% of its family
the share of years revenue rosebottom 44% of its family
the share of filed years with a profittop 18% of its family
the deepest fall from a revenue peak34.5%top 40% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

as filed

7.4/10

How has it treated the people who own it?

Share count grew 1.0% a year. 29% of cash flow returned. Insiders: 0 sales, 0 purchases.

weight 22% of this tense · 74th percentile among 80 sector filers · read for its shareholders

From the record

Over the 3 fiscal years to 2025-12-31, HUTCHMED (China) Limited's diluted share count grew about 1.0% a year, and dividends and buybacks returned about 29% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 0 sales and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

What it rests on

the share count over the yearstop 16% of its family
cash returned against operating cash flowtop 35% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

● Present

What are they doing right now?

6.7/1040% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

6.9/10

Is it financially healthy right now?

ROE 37%: 37¢ of profit per shareholder dollar. Leverage 29%: owes 29¢ per asset dollar.

weight 45% of this tense · 69th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, HUTCHMED (China) Limited earned about 37 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 12 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 29 cents per dollar of assets, and net share issuance: its share count was unchanged over the year (the filed statements).

What it rests on

what it owes per dollar of assetstop 45% of its family
return on equitytop 4% of its family
gross profit against assetsbottom 34% of its family
the share count against the year beforetop 9% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

7.6/10

How strong is its position in its industry?

top 24% of 315 in its family; net margin 83.3%.

weight 33% of this tense · 76th percentile among 315 sector filers · read for its customers

From the record

HUTCHMED (China) Limited's standing among 315 graded names in its industry family: revenue of $549 million in fiscal 2025 ranks in the top 18% by size; a net margin of 83.3% ranks in the top 3%; revenue growth of 8.8% a year over the last 3 filed years ranks in the top 49% (its annual reports).

What it rests on

revenue against the family$549Mtop 18% of its family
net margin83.3%top 3% of its family
three-year revenue growth8.8%top 49% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

5.0/10

What are the people in charge doing?

SI estimate 5.0/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 371 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-10 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 371 members with one.
What the record cannot read: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-10 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned: family median, 371 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: HUTCHMED (China) Limited's leadership is put at 5.0 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-10 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 371 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

4.0/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed

3.3/10

How much room does it have to grow?

bottom 33% of 273 in its family for room to expand.

weight 45% of this tense · 33rd percentile among 273 sector filers · read for itself

From the record

HUTCHMED (China) Limited's room to grow, from the newest filed statements (fiscal 2025): cash of $71 million against debt of $68 million leaves 0.2% of its assets as net cash, bottom 14% of its family; cash from operations less capital spending is -14.4% of revenue (top 35%); a gross margin of 38.7% (bottom 22%); research spending of 27% of revenue (bottom 33%) (its annual report).

What it rests on

cash less debt against assets0.2%bottom 14% of its family
cash from operations less capital spending against revenue-14.4%top 35% of its family
gross margin38.7%bottom 22% of its family
research spending against revenue27.0%bottom 33% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

3.3/10

What could actually drive growth from here?

bottom 33% of 306 in its family for growth drivers.

weight 33% of this tense · 33rd percentile among 306 sector filers · read for its customers

From the record

HUTCHMED (China) Limited's growth drivers, from the filed years to fiscal 2025: revenue grew 8.8% a year over the last three filed years against 10.9% over all 10, slowing (bottom 49% of its family); the newest year grew -13% (bottom 29%); research spending grew -27.4% a year (bottom 14%); capital spending grew -27.2% a year (bottom 40%) (its annual reports). HUTCHMED (China) Limited reported 2 lines of business in fiscal 2025: Oncology Or Immunology at $286 million (52%), Other Ventures at $263 million (48%); 0 of 2 grew against the year before (its annual report).

What it rests on

three-year growth against the whole span-2.2 points a yearbottom 49% of its family
the newest year's revenue growth-13.0%bottom 29% of its family
three-year growth of research spending-27.4%bottom 14% of its family
three-year growth of capital spending-27.2%bottom 40% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

6.5/10

Did its newest year beat what its own record pointed to?

top 35% of 233 in its family for expectations against reality.

weight 22% of this tense · 65th percentile among 233 sector filers · read for its shareholders

From the record

HUTCHMED (China) Limited's newest year against its own record: revenue of $549 million in fiscal 2025 came in 28.4% below the $766 million its prior three years' pace pointed to (bottom 27% of its family); net income of $457 million against a prior three-year average of $74 million (top 2%); a net margin of 83.3% against -22.2% before (top 31%) (its annual reports).

What it rests on

revenue against the prior three years' pace-28.4%bottom 27% of its family
net income against the prior three years' averagefive times its prior average or moretop 2% of its family
net margin against its prior averageup more than 100 pointstop 31% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton HCM · research, not advice